Sparta Systems Names Enterprise Software Veteran Eileen Martinson as Chief Executive Officer

Sparta Systems Names Enterprise Software Veteran
Eileen Martinson as Chief Executive Officer

Senior Executive Joins Sparta Systems to Continue the Company's Momentum
Following Three Consecutive Record Quarters

HOLMDEL, N.J. - July 19, 2011 - Sparta Systems, Inc., the maker of TrackWise® quality management software and the market leader in enterprise quality and compliance management solutions, today announced that Eileen Martinson (formerly McPartland) has been appointed Chief Executive Officer. With more than 25 years of experience driving professional services, sales and operations at global industry leaders such as SAP America, Oracle, Misys and Siebel, Martinson has a long-standing record of developing global business strategies and directing the worldwide growth of enterprise technology companies. She succeeds James E. McGowan as the company's CEO.

Prior to joining Sparta Systems, Martinson was Chief Operating Officer of Allscripts (NASDAQ: MDRX), a leading provider of clinical software, connectivity and information solutions for the healthcare industry. While at Allscripts, she managed more than 4,000 global associates, $1 billion in annual revenue and a vast product portfolio, and was instrumental in completing its $1.3 billion merger with Eclipsys Corporation, expanding the company's healthcare solutions to address the hospital marketplace.

"Sparta Systems has a strong reputation for providing companies in highly regulated industries with solutions that meet their quality and compliance needs, while adding efficiency and effectiveness to critical business processes," said Martinson. "With a strong foundation in place and significant potential for growth, I look forward to working with the Sparta Systems team, customers and partners to enter the next phase of expansion as we pursue new opportunities in both existing and emerging markets."

Martinson was previously executive vice president of global sales and services at Misys plc and senior vice president at Oracle Consulting. Prior to these global leadership positions she served as senior vice president of global services at Siebel, executive vice president for global product solutions and delivery at Ariba, senior vice president of research at Gartner and executive vice president SAP America.

"We are pleased to welcome Eileen Martinson to Sparta Systems and are confident that her qualifications and experience will help to deliver additional customer value while continuing to drive growth in the business," said Daniel G. Tully, Managing Director, Altaris Capital Partners LLC. "We would also like to thank James E. McGowan for his tremendous contribution to Sparta Systems and the significant role he played in the company's growth."

For more information on Martinson and Sparta Systems, visit www.spartasystems.com.

 

About Sparta Systems

Sparta Systems, Inc. is an industry leader for global quality and compliance management systems. Its TrackWise® product is a Web-based software application used by quality, manufacturing and regulatory affairs professionals to manage quality and compliance issues across the enterprise. The company has more than 15 years of experience and an extensive customer base in the life sciences and other highly regulated industries. Sparta Systems offers its customers a complete solution for global quality management needs, including the onsite support required throughout the project lifecycle. Read more about Sparta Systems and TrackWise software on the corporate website and blog www.spartasystems.com/blog.spartasystems.com.

 

Sparta Systems and TrackWise are trademarks or registered trademarks of Sparta Systems, Inc. All other marks are trademarks of their respective companies.

 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.